Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Halozyme Therapeutics, Inc. Transaction History
Mitsubishi Ufj Kokusai Asset Management Co., Ltd.
- $92.2 Billion
- Q3 2024
A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 362 shares of HALO stock, worth $19,113. This represents 0.0% of its overall portfolio holdings.
Number of Shares
362
Previous 85
325.88%
Holding current value
$19,113
Previous $4,000
400.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
542Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$930 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$681 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$350 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$215 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$180 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.35B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...